Authors

    Language

    English

    Publication Date

    10-1-2023

    Journal

    Neural Regeneration Research

    DOI

    10.4103/1673-5374.369095

    PMID

    37056121

    PMCID

    PMC10328265

    PubMedCentral® Posted Date

    3-3-2023

    PubMedCentral® Full Text Version

    Post-print

    Abstract

    Type 2 diabetes mellitus patients have a markedly higher risk of developing dementia. While multiple factors contribute to this predisposition, one of these involves the increased secretion of amylin, or islet amyloid polypeptide, that accompanies the pathophysiology of type 2 diabetes mellitus. Islet amyloid polypeptide accumulation has undoubtedly been implicated in various forms of dementia, including Alzheimer’s disease and vascular dementia, but the exact mechanisms underlying islet amyloid polypeptide’s causative role in dementia are unclear. In this review, we have summarized the literature supporting the various mechanisms by which islet amyloid polypeptide accumulation may cause neuronal damage, ultimately leading to the clinical symptoms of dementia. We discuss the evidence for islet amyloid polypeptide deposition in the brain, islet amyloid polypeptide interaction with other amyloids implicated in neurodegeneration, neuroinflammation caused by islet amyloid polypeptide deposition, vascular damage induced by islet amyloid polypeptide accumulation, and islet amyloid polypeptide-induced cytotoxicity. There are very few therapies approved for the treatment of dementia, and of these, clinical responses have been controversial at best. Therefore, investigating new, targetable pathways is vital for identifying novel therapeutic strategies for treating dementia. As such, we conclude this review by discussing islet amyloid polypeptide accumulation as a potential therapeutic target not only in treating type 2 diabetes mellitus but as a future target in treating or even preventing dementia associated with type 2 diabetes mellitus.

    Keywords

    Alzheimer’s disease, amylin, amyloid, dementia, diabetes, human islet amyloid polypeptide, islet amyloid polypeptide, protofibrils, type 2 diabetes mellitus, vascular dementia

    Published Open-Access

    yes

    Share

    COinS
     
     

    To view the content in your browser, please download Adobe Reader or, alternately,
    you may Download the file to your hard drive.

    NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.